Cardiovascular disease in the polycystic ovary syndrome: New insights and perspectives

被引:122
|
作者
Cussons, AJ
Stuckey, BGA
Watts, GF
机构
[1] Univ Western Australia, Sch Med & Pharmacol, Royal Perth Hosp Unit, Perth, WA 6847, Australia
[2] Keogh Inst Med Res, Nedlands, WA, Australia
[3] Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia
基金
英国医学研究理事会;
关键词
polycystic ovary syndrome; cardiovascular function and structure; cardiovascular risk; insulin resistance;
D O I
10.1016/j.atherosclerosis.2005.10.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The new millennium has brought intense focus of interest on the risk of cardiovascular disease in women. The polycystic ovary syndrome (PCOS) is a common endocrine disorder in women characterised by hyperandrogenism and oligomenorrhoea. Most women with PCOS also exhibit features of the metabolic syndrome, including insulin resistance, obesity and dyslipidaemia. While the association with type 2 diabetes is well established, whether the incidence of cardiovascular disease is increased in women with PCOS remains unclear. Echocardiography, imaging of coronary and carotid arteries, and assessments of both endothelial function and arterial stiffness have recently been employed to address this question. These studies have collectively demonstrated both structural and functional abnormalities of the cardiovascular system in PCOS. These alterations, however, appear to be related to the presence of individual cardiovascular risk factors, particularly insulin resistance, rather than to the presence of PCOS and hyperandrogenaemia per se. However, given the inferential nature of the evidence to date, more rigorous cohort studies of long-term cardiovascular outcomes and clinical trials of risk factor modification are required in women with PCOS. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:227 / 239
页数:13
相关论文
共 50 条
  • [1] Polycystic ovary syndrome and cardiovascular disease
    Jacobs, HS
    [J]. FSH ACTION AND INTRAOVARIAN REGULATION, 1997, 6 : 247 - 252
  • [2] Cardiovascular disease in polycystic ovary syndrome
    Atkin, S. L.
    [J]. CLINICAL ENDOCRINOLOGY, 2013, 78 (06) : 823 - 824
  • [3] New perspectives in polycystic ovary syndrome
    DiamantiKandarakis, E
    Dunaif, A
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1996, 7 (08): : 267 - 271
  • [4] Subclinical cardiovascular disease and polycystic ovary syndrome
    Gomez, Joanne Michelle D.
    VanHise, Katherine
    Stachenfeld, Nina
    Chan, Jessica L.
    Merz, Noel Bairey
    Shufelt, Chrisandra
    [J]. FERTILITY AND STERILITY, 2022, 117 (05) : 912 - 923
  • [5] Polycystic ovary syndrome: associations with cardiovascular disease
    Benham, J. L.
    Goldberg, A.
    Teede, H.
    Tay, C. T.
    [J]. CLIMACTERIC, 2024, 27 (01) : 47 - 52
  • [6] Polycystic ovary syndrome and cardiovascular disease risk
    Legro R.S.
    [J]. Current Cardiovascular Risk Reports, 2009, 3 (1) : 65 - 70
  • [7] New adolescent polycystic ovary syndrome perspectives
    Alemzadeh, R.
    Kansra, A. R.
    [J]. MINERVA PEDIATRICA, 2011, 63 (01) : 35 - 47
  • [8] New insights into the genetics of polycystic ovary syndrome
    Ricardo Azziz
    [J]. Nature Reviews Endocrinology, 2016, 12 : 74 - 75
  • [9] New insights into the genetics of polycystic ovary syndrome
    Azziz, Ricardo
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2016, 12 (02) : 74 - 75
  • [10] Cardiovascular Risk and Subclinical Cardiovascular Disease in Polycystic Ovary Syndrome
    Studen, Katica Bajuk
    Sever, Mojca Jensterle
    Pfeifer, Marija
    [J]. POLYCYSTIC OVARY SYNDROME: NOVEL INSIGHT INTO CAUSES AND THERAPY, 2013, 40 : 64 - 82